SG171691A1 - Biomarkers for diagnosing multiple sclerosis, and methods thereof - Google Patents

Biomarkers for diagnosing multiple sclerosis, and methods thereof

Info

Publication number
SG171691A1
SG171691A1 SG201103496-4A SG2011034964A SG171691A1 SG 171691 A1 SG171691 A1 SG 171691A1 SG 2011034964 A SG2011034964 A SG 2011034964A SG 171691 A1 SG171691 A1 SG 171691A1
Authority
SG
Singapore
Prior art keywords
multiple sclerosis
methods
intensities
biomarkers
progressive
Prior art date
Application number
SG201103496-4A
Other languages
English (en)
Inventor
Lisa Cook
Original Assignee
Phenomenome Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomenome Discoveries Inc filed Critical Phenomenome Discoveries Inc
Publication of SG171691A1 publication Critical patent/SG171691A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/103—Extraction or purification by physical or chemical treatment of natural phosphatides; Preparation of compositions containing phosphatides of unknown structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/46—Unsaturated compounds containing hydroxy or O-metal groups containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/62—Unsaturated compounds containing ether groups, groups, groups, or groups containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
SG201103496-4A 2006-05-26 2007-05-24 Biomarkers for diagnosing multiple sclerosis, and methods thereof SG171691A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80326706P 2006-05-26 2006-05-26

Publications (1)

Publication Number Publication Date
SG171691A1 true SG171691A1 (en) 2011-06-29

Family

ID=38778055

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201103496-4A SG171691A1 (en) 2006-05-26 2007-05-24 Biomarkers for diagnosing multiple sclerosis, and methods thereof

Country Status (10)

Country Link
US (1) US20100062472A1 (ja)
EP (3) EP2644588A3 (ja)
JP (3) JP2009538416A (ja)
KR (1) KR20090013207A (ja)
CN (1) CN101479230A (ja)
AU (1) AU2007266218C1 (ja)
BR (1) BRPI0712812A2 (ja)
CA (2) CA2835964C (ja)
SG (1) SG171691A1 (ja)
WO (1) WO2007137410A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095275A1 (en) 2007-02-08 2008-08-14 Phenomenome Discoveries Inc. Methods for the treatment of senile dementia of the alzheimer's type
JP5117336B2 (ja) * 2008-09-18 2013-01-16 国立大学法人 千葉大学 多発性硬化症またはｎｍｏの検査マーカーの測定方法
EP2353004B1 (en) * 2008-11-12 2018-01-03 Yeda Research and Development Co. Ltd. Diagnosis of multiple sclerosis
CN101990050A (zh) * 2009-07-31 2011-03-23 威海华菱光电有限公司 接触式图像传感器专用玻璃板及其制备方法
CA2797960A1 (en) 2009-10-01 2011-04-07 Phenomenome Discoveries Inc. Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
AU2010326737A1 (en) * 2009-12-01 2012-06-07 Metanomics Health Gmbh Means and methods for diagnosing multiple sclerosis
GB201202092D0 (en) * 2012-02-07 2012-03-21 Isis Innovation Diagnosing multiple sclerosis
US20160237012A1 (en) * 2015-02-17 2016-08-18 Golden Biotechnology Corporation Anticancer agents and process of making thereof
WO2019009446A1 (ko) * 2017-07-05 2019-01-10 가천대학교 산학협력단 다발성 경화증 및 시신경 척수염 범주 질환을 구별하는 방법
US20220049309A1 (en) 2018-12-12 2022-02-17 Hadasit Medical Research Srvices And Development Ltd. Markers of disease prognosis in multiple sclerosis
RU2694614C1 (ru) * 2019-01-22 2019-07-17 Общество с ограниченной ответственностью "ВЕСТТРЭЙД ЛТД" (ООО "ВЕСТТРЭЙД ЛТД") Способ определения активности патологического процесса у больных рассеянным склерозом

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292459A (en) * 1975-07-16 1981-09-29 Scm Corporation Coupling reaction involving a Grignard and allylic halide
JP2758403B2 (ja) * 1988-03-29 1998-05-28 エーザイ株式会社 クロマン誘導体及びαートコフェロールの製造方法
CA2298181C (en) * 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
JP4422291B2 (ja) * 2000-04-21 2010-02-24 大日精化工業株式会社 ヒトメダラシンの免疫学的測定方法
EP2330219A3 (en) * 2000-04-14 2011-11-23 Metabolon, Inc. Method for drug discovery, disease treatment and diagnosis using metabolomics
ES2568491T3 (es) * 2002-06-19 2016-04-29 Gnt Pharma Co., Ltd. Derivados de tetrafluorobencilo y composición farmacéutica para prevenir y tratar enfermedades neurodegenerativas agudas y crónicas en el sistema nervioso central que contiene dichos derivados
US20050064516A1 (en) * 2003-09-18 2005-03-24 Kantor Aaron B. Biological markers for diagnosing multiple sclerosis
JP2005160440A (ja) * 2003-12-05 2005-06-23 Hitachi Ltd 多発性硬化症に関連する遺伝子の発現測定方法、多発性硬化症関連遺伝子の発現を測定するためのチップ、多発性硬化症の罹患を判断するための遺伝子群、多発性硬化症の評価方法
WO2005113831A2 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Biomarkers for multiple sclerosis and methods of use thereof
WO2006005583A2 (en) * 2004-07-12 2006-01-19 Geneprot Inc. Secreted polypeptide species involved in multiple sclerosis
CA2881326A1 (en) 2005-09-12 2007-03-22 Phenomenome Discoveries Inc. Methods for the diagnosis of colorectal cancer and ovarian cancer health states

Also Published As

Publication number Publication date
EP2644588A3 (en) 2013-12-25
WO2007137410A1 (en) 2007-12-06
JP2009538416A (ja) 2009-11-05
CA2651724C (en) 2014-07-08
JP2015052611A (ja) 2015-03-19
EP3231789A1 (en) 2017-10-18
CA2651724A1 (en) 2007-12-06
KR20090013207A (ko) 2009-02-04
CA2835964C (en) 2016-07-19
CN101479230A (zh) 2009-07-08
EP2021313A4 (en) 2011-05-18
EP2644588A2 (en) 2013-10-02
JP2016197123A (ja) 2016-11-24
US20100062472A1 (en) 2010-03-11
BRPI0712812A2 (pt) 2012-10-23
AU2007266218A1 (en) 2007-12-06
AU2007266218C1 (en) 2013-05-23
JP5977795B2 (ja) 2016-08-24
CA2835964A1 (en) 2007-12-06
EP2021313A1 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
Lehrner et al. Subjective memory complaints, depressive symptoms and cognition in patients attending a memory outpatient clinic
Ehreke et al. Is the Clock Drawing Test a screening tool for the diagnosis of mild cognitive impairment? A systematic review
Oguh et al. Caregiver strain in Parkinson's disease: national Parkinson Foundation Quality Initiative study
ATE533061T1 (de) Verfahren zur diagnose bakterieller infektionen
EP2770328A3 (en) Method to diagnose pancreatic cancer
WO2005020784A3 (en) Surrogate cell gene expression signatures for evaluating the physical state of a subject
JP2009538607A5 (ja)
Moorhouse et al. Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study
HK1063423A1 (en) Methods to diagnose treat and prevent bone loss
EP2851369A3 (en) Methods for the diagnosis of dementia and other neurological disorders
WO2005114190A3 (en) Methods of identifying biomarkers
EP3293522A3 (en) Lipidomic biomarkers for identification of high-risk coronary artery disease patients
MX2009004463A (es) Ensayo para anticuerpos de troponina cardiaca.
WO2009152607A8 (en) Methods and kits for diagnosing neurodegenerative disease
WO2009040782A3 (en) A method of assessing colorectal cancer status in an individual
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
IT201800007264A1 (it) Metodo per la diagnosi in vitro di carcinoma della prostata mediante biomarcatori urinari
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof
ATE483982T1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
WO2006099543A3 (en) Methods for assessing antibody-mediated cytotoxicity
CA2680748A1 (en) Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging
Shook et al. Racing against the clock: recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient